Literature DB >> 1279378

Modulation of (+)-[3H]pentazocine binding to guinea pig cerebellum by divalent cations.

A S Basile1, I A Paul, A Mirchevich, G Kuijpers, B De Costa.   

Abstract

The ability of cations to modulate the binding of the sigma 1 receptor-selective ligand (+)-[3H]pentazocine to guinea pig cerebellum was investigated. Di- and trivalent cations biphasically inhibited (+)-[3H]pentazocine binding, revealing multiple affinity states. The rank order of potency of these cations (based on the high affinity component of inhibition) was Zn2+ > Co2+ >> La3+ = Ni2+ = Cd2+ = Mn2+ = Gd2+ > Ba2+ = Sr2+ >> Mg2+ > Ca2+. The inhibition of 1,3-[3H]di(2-tolyl)guanidine binding to the sigma 2 receptor by these cations differed qualitatively and quantitatively from their effects on (+)-[3H]pentazocine binding. Although monovalent cations decreased the Kd for (+)-[3H]pentazocine binding, divalent cations split (+)-[3H]pentazocine binding into low and high affinity components. The Bmax of the high affinity component decreased with increasing divalent cation concentrations. Both mono- and divalent cations significantly reduced the rate of association of (+)-[3H]pentazocine with the sigma 1 receptor without altering the dissociation rate. (+)-[3H]Pentazocine binding was not altered by guanine nucleotides or by treatment with cholera or pertussis toxins. However, nonselective cation channel blockers (cinnarizine, hydroxyzine, prenylamine, amiodarone, and proadifen) potently inhibited (+)-[3H]pentazocine binding. These results indicate that physiologically relevant concentrations of divalent cations allosterically modulate (+)-[3H]pentazocine binding to the sigma 1 receptor, to reveal multiple affinity states. These sites do not represent sigma 1 to sigma 2 subtype interconversion or ternary complex formation with guanine nucleotide-binding proteins. However, the rank order of cation potency and the inhibition of binding by cation channel blockers is consistent with a potential role for sigma receptors as constituents of cation channels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279378

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  [(3)H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance.

Authors:  D Morin; R Sapena; A Elimadi; B Testa; S Labidalle; A Le Ridant; J P Tillement
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

4.  Characterization of [3H]pentazocine binding sites in post-mortem human frontal cortex.

Authors:  J Kornhuber; K Schoppmeyer; C Bendig; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands.

Authors:  J E Bermack; G Debonnel
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma.

Authors:  Lucia Longhitano; Carlo Castruccio Castracani; Daniele Tibullo; Roberto Avola; Maria Viola; Giuliano Russo; Orazio Prezzavento; Agostino Marrazzo; Emanuele Amata; Michele Reibaldi; Antonio Longo; Andrea Russo; Nunziatina Laura Parrinello; Giovanni Li Volti
Journal:  Oncotarget       Date:  2017-07-25

7.  Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis.

Authors:  Luz Romero; Enrique Portillo-Salido
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.